• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SPIRONOLACTONE Drug Record

  • Summary
  • Interactions
  • Claims
  • SPIRONOLACTONE chembl:CHEMBL1393 Approved

    Alternate Names:

    SPIRETIC
    SPIROCTAN 100
    SPIROCTAN 25
    SC-9420
    NSC-150399
    ALDACTONE
    ABBOLACTONE
    SPIRONOLACTONE
    LARACTONE
    SPIROCTAN 50
    SPIROSPARE 100
    DIATENSEC
    GX SPIRONOL
    CAROSPIR
    SPIROSPARE 25
    SPIRONOLATTONE
    ESPIRONOLACTONA
    SPIRNOLACTONE
    SPIRACTIN
    SPIROTONE
    ALDACTONE®
    SPIRONOLACTONUM
    pubchem.compound:5833
    chembl:CHEMBL1393
    drugbank:00421
    chemidplus:52-01-7
    rxcui:9997

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antihypertensive agent
    Drug Class antihypertensive agents
    Year of Approval 1960
    Drug Class diuretics
    (4 More Sources)

    Publications:

    Cicoira M et al., 2004, Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure., Am J Med
    Ghanem et al., 2006, Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin., J. Pharmacol. Exp. Ther.
    Kim KM et al., 2012, Pharmacogenetics and healthcare outcomes in patients with chronic heart failure., Eur J Clin Pharmacol
    Ye et al., 2009, Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis., Horm. Metab. Res.
    Fujita et al., 1982, Effect of spironolactone on hepatic microsomal monooxygenase and azoreductase activities., Res. Commun. Chem. Pathol. Pharmacol.
    Sica, 2005, Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis., Heart Fail Rev
    Rogerson et al., 2003, Determinants of spironolactone binding specificity in the mineralocorticoid receptor., J. Mol. Endocrinol.
    Rogerson et al., 2004, Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor., Clin. Exp. Pharmacol. Physiol.
    Gertner et al., 2004, Aldosterone decreases UT-A1 urea transporter expression via the mineralocorticoid receptor., J. Am. Soc. Nephrol.
    Frishman et al., 2004, Aldosterone and aldosterone antagonism in systemic hypertension., Curr. Hypertens. Rep.
    Sitruk-Ware, Progestogens in hormonal replacement therapy: new molecules, risks, and benefits., Menopause
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Rossi et al., 2005, Aldosterone as a cardiovascular risk factor., Trends Endocrinol. Metab.
    Kretschmer XC et al., 2005, CAR and PXR: xenosensors of endocrine disrupters?, Chem Biol Interact
    Matsumoto et al., 2006, The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy., Metab. Clin. Exp.
    Cheng et al., 1976, Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria., Endocrinology
    Yang YY et al., 2011, Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites., Clin Sci (Lond)
    Miura et al., 2006, Anti-inflammatory effect of spironolactone on human peripheral blood mononuclear cells., J. Pharmacol. Sci.
    Gauer et al., 2007, Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor., Nephrol. Dial. Transplant.
  • SPIRONOLACTONE   NR3C2

    Interaction Score: 2.17

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Mineralocorticoid receptor antagonist
    Direct Interaction yes
    Trial Name HTI-101

    PMIDs:
    15947888 14664717 15554912 14978157 15128471 11791081 11752352 15808807


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • SPIRONOLACTONE   CYP4A11

    Interaction Score: 1.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SPIRONOLACTONE   ADD1

    Interaction Score: 1.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21692745


    Sources:
    PharmGKB

  • SPIRONOLACTONE   ADIPOQ

    Interaction Score: 1.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17142138


    Sources:
    NCI

  • SPIRONOLACTONE   CYP7B1

    Interaction Score: 0.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    976190


    Sources:
    NCI

  • SPIRONOLACTONE   CCN2

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17602195


    Sources:
    NCI

  • SPIRONOLACTONE   CYP1A1

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7079590


    Sources:
    NCI

  • SPIRONOLACTONE   NOS3

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22543981


    Sources:
    PharmGKB

  • SPIRONOLACTONE   CYP1B1

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7079590


    Sources:
    NCI

  • SPIRONOLACTONE   ACE

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15121491


    Sources:
    PharmGKB

  • SPIRONOLACTONE   TNF

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16837769


    Sources:
    NCI

  • SPIRONOLACTONE   ADRB1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22543981


    Sources:
    PharmGKB

  • SPIRONOLACTONE   NR1I2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16054614


    Sources:
    PharmGKB

  • SPIRONOLACTONE   ADRB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22543981


    Sources:
    PharmGKB

  • SPIRONOLACTONE   ABCB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16740618


    Sources:
    NCI PharmGKB

  • SPIRONOLACTONE   THRB

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SPIRONOLACTONE   PPARG

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SPIRONOLACTONE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7079590


    Sources:
    NCI

  • SPIRONOLACTONE   AR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    18819053


    Sources:
    DTC

  • TEND: SPIRONOLACTONE

    • Version: 01-August-2011

    Alternate Names:
    SPIRONOLACTONE Primary Drug Name

    Drug Info:
    Drug Class diuretics
    Year of Approval 1960
    Drug Class antihypertensive agents

    Publications:

  • TdgClinicalTrial: SPIRONOLACTONE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antihypertensive agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: SPIRONOLACTONE

    • Version: 14-September-2017

    Alternate Names:
    C840 NCI drug code

    Drug Info:

    Publications:
    Fujita et al., 1982, Effect of spironolactone on hepatic microsomal monooxygenase and azoreductase activities., Res. Commun. Chem. Pathol. Pharmacol.
    Miura et al., 2006, Anti-inflammatory effect of spironolactone on human peripheral blood mononuclear cells., J. Pharmacol. Sci.
    Ghanem et al., 2006, Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin., J. Pharmacol. Exp. Ther.

  • PharmGKB: spironolactone

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Cicoira M et al., 2004, Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure., Am J Med
    Kim KM et al., 2012, Pharmacogenetics and healthcare outcomes in patients with chronic heart failure., Eur J Clin Pharmacol
    Yang YY et al., 2011, Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites., Clin Sci (Lond)

  • DTC: SPIRONOLACTONE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1393 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Spironolactone

    • Version: 2020.06.01

    Alternate Names:
    D0EP0C TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1393

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1393

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21